Thrombopoietin Level Predicts Response to Treatment with Eltrombopag and Romiplostim in Immune Thrombocytopenia

被引：0
|
作者：
Al-Samkari, Hanny [1 ]
Kuter, David J. [2 ]
机构：
[1] Harvard Univ, Dana Farber Canc Inst, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117267
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
734
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation
    Haixia Fu
    Meng Lv
    Huixin Liu
    Yuqian Sun
    Yuanyuan Zhang
    Xiaodong Mo
    Tingting Han
    Fengrong Wang
    Chenhua Yan
    Yu Wang
    Jun Kong
    Wei Han
    Huan Chen
    Yao Chen
    Yuhong Chen
    Lanping Xu
    Kaiyan Liu
    Xiaojun Huang
    Xiaohui Zhang
    [J]. Bone Marrow Transplantation, 2023, 58 : 1368 - 1376
  • [42] Impact of Eltrombopag Therapy in Different Lines of Treatment on Response in Patients with Immune Thrombocytopenia
    Karismaz, Abdulkadir
    Cavdar, Vahit Can
    Serin, Istemi
    Eren, Rafet
    [J]. ISTANBUL MEDICAL JOURNAL, 2024, 25 (03): : 241 - 244
  • [43] Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile
    Cheng, Gregory
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (03) : 155 - 164
  • [44] Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
    Cai Xuan
    Fu Haixia
    Zhao Xiangyu
    Lu Jin
    Jiang Qian
    Chang Yingjun
    Huang Xiaojun
    Zhang Xiaohui
    [J]. 中华医学杂志(英文版), 2022, 135 (19)
  • [45] Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment
    Cantoni, Nathan
    Heizmann, Marc
    Bargetzi, Mario
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (05) : 639 - 641
  • [46] Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients
    Khellaf, Mehdi
    Viallard, Jean-Francois
    Hamidou, Mohamed
    Cheze, Stephane
    Lefrere, Francois
    Fain, Olivier
    Audia, Sylvain
    Jardin, Fabrice
    Gyan, Emmanuel
    Durand, Jean Marc
    Haioun, Corinne
    Bierling, Philippe
    Michel, Marc
    Godeau, Bertrand
    [J]. BLOOD, 2012, 120 (21)
  • [47] Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Roy, Anuja
    Elliott, Brian
    Briggs, Andrew
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 715 - 721
  • [48] Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
    Patwardhan, Pallavi
    Proudman, David
    Allen, Jeffrey
    Lucas, Sedge
    Nellesen, Dave
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (10): : 1447 - 1456
  • [49] Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
    Cai, Xuan
    Fu, Haixia
    Zhao, Xiangyu
    Lu, Jin
    Jiang, Qian
    Chang, Yingjun
    Huang, Xiaojun
    Zhang, Xiaohui
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (19) : 2344 - 2350
  • [50] Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPORA) in Immune Thrombocytopenia (ITP)
    Sayed, Anwar A.
    Malik, Amna
    Ayoola, Grace
    Lucchini, Elisa
    Candrianita, Sasfia
    Tan, Michelle H.
    Vladescu, Camelia
    Paul, Deena
    Hart, Alice C. J.
    Khoder, Ahmad
    Imami, Nesrina
    Cooper, Nichola
    [J]. BLOOD, 2019, 134
12345